npj Vaccines (Nov 2021)

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

  • Mayuresh M. Abhyankar,
  • Barbara J. Mann,
  • Jeffrey M. Sturek,
  • Savannah Brovero,
  • G. Brett Moreau,
  • Anjali Sengar,
  • Crystal M. Richardson,
  • Sayeh Agah,
  • Anna Pomés,
  • Peter M. Kasson,
  • Mark A. Tomai,
  • Christopher B. Fox,
  • William A. Petri

DOI
https://doi.org/10.1038/s41541-021-00399-0
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 6

Abstract

Read online

Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.